Cathie Wood’s ARK Invest has made significant waves in the biotech sector by increasing its stake in Intellia Therapeutics. On Thursday, the firm acquired 56,769 shares split between two of its exchange-traded funds, showcasing its confidence in the company’s future. With ARKK purchasing 48,178 shares and ARKG adding 8,591 shares, the total investment amounted to approximately $682,000.
This acquisition marks the third consecutive day of purchasing Intellia stock, indicating a firm commitment to the company. Earlier in the week, ARK had acquired 99,292 shares on Monday, followed by another 40,067 shares on Tuesday. Following these announcements, Intellia’s stock rose over 2% in after-hours trading, reflecting positive market sentiment.
Intellia’s Focus on Gene-Editing
Intellia Therapeutics specializes in developing gene-editing therapies utilizing CRISPR technology. The clinical-stage biotech firm is primarily focused on addressing rare diseases, which presents both challenges and opportunities. In 2026, the stock has rebounded sharply, with a 32% increase since the beginning of the year, signaling recovery after a tumultuous 2025.
That previous year proved challenging, as Intellia’s stock declined by 23% due to a tragic incident during a clinical trial. A male patient in his 80s passed away while undergoing an experimental treatment called Nexiguran ziclumeran, designed to tackle transthyretin amyloidosis with cardiomyopathy, a rare and serious heart condition.
Recovery and Growth Potential
Despite the setbacks, Intellia’s stock has shown resilience, gaining about 26% over the past year. Analysts attribute this growth to steady progress in clinical trials and a renewed sense of investor confidence. The company’s innovative approach to gene editing continues to attract attention, and its stock performance suggests that investors are optimistic about its potential.
As of December 31, Intellia ranks as the 23rd largest holding in ARK’s portfolio. Within the ARKG fund, it finds itself among the bottom five positions, indicating that while it may not be the top performer, ARK still sees value in its future prospects. The leading holdings in ARKG include Crispr Therapeutics, Tempus AI, and Guardant Health, all of which highlight ARK’s commitment to the cutting-edge field of genomics.
Analyst Ratings and Market Outlook
The recent three-day purchasing spree, totaling nearly 196,000 shares, illustrates sustained confidence in Intellia’s future. Analysts maintain a generally positive outlook on the stock, with a consensus rating of Moderate Buy based on 22 opinions. Among these, nine analysts recommend it as a Buy, while twelve suggest holding, and one advises selling.
The average price target for Intellia stands at $16.41, indicating a potential upside of roughly 38% from current trading levels. This bullish forecast aligns with ARK’s ongoing purchases, which reflect a strategic bet on the growth potential of the gene-editing market.
ARK Invest’s Strategy
ARK Invest’s strategy emphasizes disruptive technologies, with a strong focus on genomics and gene editing as key themes. The recent investment of about $1.1 million into Intellia reflects ARK’s belief in the transformative potential of these technologies. By continuing to bolster its position in Intellia, ARK is signaling that it sees significant growth opportunities ahead, despite the challenges the company has faced.
Through these strategic moves, ARK aims to capitalize on the advancements in gene editing, which hold promise for tackling some of the most pressing medical challenges today.
Conclusion
ARK Invest’s sustained acquisition of Intellia Therapeutics stock highlights its confidence in the company’s innovative potential and the broader gene-editing sector. As the biotech landscape evolves, Intellia’s progress in clinical trials and its focus on rare diseases position it well for future success. The firm’s strategic investments underscore a belief in the transformative power of genomics, suggesting that the journey ahead for Intellia may be both dynamic and rewarding.
- ARK Invest has acquired nearly 196,000 shares of Intellia in three days.
- Intellia’s stock is up 32% in 2026 after a challenging previous year.
- Analysts maintain a consensus rating of Moderate Buy for Intellia.
- The average price target for Intellia suggests a potential upside of 38%.
- ARK’s investment strategy focuses on disruptive technologies, particularly in genomics.
Read more → blockonomi.com